Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
ISSN
09598049
Date Issued
2019
Author(s)
DOI
10.1016/j.ejca.2019.06.002
Subjects